Global API sourcing simplified
We connect API buyers and suppliers worldwide with speed, trust, and full transparency.
teaser-1024x654-1

Conjugated Estrogen API Manufacturers & Suppliers

0 verified results
Get full market intelligence report
Get full market intelligence report
Full access. Full negotiation power All Conjugated Estrogen data. Full access. Full negotiation power

Commercial-scale Suppliers

No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Conjugated Estrogen is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Conjugated Estrogen or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.
When insight is your advantage
Full data, full access, full negotiation power
Total market transparency Total market transparency
|
Supplier trade data access Supplier trade data access
|
Buyer / supplier flow comparison Buyer / supplier flow comparison
Trusted by 30,000+ registered pharma professionals:
Reach multinationals, SMEs, compounding pharmacies & more!
Procaps
Pfizer
Reckitt
Sanofi
Blau
Abbvie

Zeaxanthin | CAS No: 144-68-3 | GMP-certified suppliers

A medication that supports ocular health by potentially reducing age-related macular degeneration progression through antioxidant and blue light filtering properties.

Therapeutic categories

AlkenesBiological FactorsCarotenoidsCyclohexanesCyclohexenesCycloparaffins
Generic name
Zeaxanthin
Molecule type
small molecule
CAS number
144-68-3
DrugBank ID
DB11176
Approval status
Approved drug, Investigational drug

Product Snapshot

  • Zeaxanthin is available in oral solid and liquid-filled capsule formulations as well as tablets
  • It is primarily used for ocular health applications
  • The product is approved and investigational in the US market

Clinical Overview

Zeaxanthin (CAS Number 144-68-3) is a naturally occurring xanthophyll carotenoid alcohol widely distributed in plants and certain microorganisms. It is structurally characterized by an oxygenated carotene backbone, specifically a long branched polyene chain with cyclic end groups. Zeaxanthin is a stereoisomer of lutein and differs primarily in spatial configuration. It confers a distinct yellow coloration to several vegetables and plant products, including paprika, corn, saffron, and wolfberries.

In humans, zeaxanthin is a predominant xanthophyll localized in the central macula of the retina where it plays a structural and functional role. Although exact pharmacodynamics and mechanism of action are not fully delineated, zeaxanthin is understood to serve as a macular pigment that may contribute to filtering high-energy blue light and act as an antioxidant. These properties underpin its use as a dietary supplement aimed at supporting ocular health and potentially mitigating the progression of age-related macular degeneration (AMD).

Pharmacokinetic data for zeaxanthin show it is absorbed via the intestinal tract, with peak plasma concentrations occurring several hours post ingestion. Being lipophilic, its bioavailability is enhanced by dietary fats. It is primarily distributed to the liver and adipose tissue, with noteworthy accumulation in ocular tissue. Metabolic pathways and elimination routes have not been extensively characterized but likely involve hepatic metabolism and biliary excretion.

Safety profiles indicate that zeaxanthin is generally well tolerated at supplemental doses. Toxicological concerns are minimal, although long-term safety data are limited. There are no significant drug interaction data available. Due to its origin from natural sources, variability in purity and isomeric composition may occur among commercial preparations.

Zeaxanthin is utilized in both the nutraceutical and food industries, including formulations for eye health and as an approved natural food pigment. When sourcing zeaxanthin API, critical quality attributes to monitor include isomeric purity, absence of contaminants or degradation products, and compliance with established pharmacopeial standards if intended for pharmaceutical use. Suppliers should provide comprehensive documentation regarding origin, manufacturing processes, and analytical characterization to ensure product consistency and regulatory compliance.

Identification & chemistry

Generic name Zeaxanthin
Molecule type Small molecule
CAS 144-68-3
UNII CV0IB81ORO
DrugBank ID DB11176

Formulation & handling

  • Zeaxanthin is a small molecule carotenoid intended for oral administration, commonly formulated as capsules or tablets.
  • Due to its high lipophilicity (LogP 8.35) and low water solubility, formulation strategies should enhance bioavailability, such as lipid-based delivery systems.
  • Stable under normal handling but sensitive to light and oxidation, requiring appropriate packaging to maintain potency.

Regulatory status

LifecycleThe API's key patents expired in 2021, allowing generic versions to enter the US market. As a result, the product is in a mature lifecycle phase characterized by established competition and stable demand.
MarketsUS
Supply Chain
Supply chain summaryThe manufacturing and supply landscape for zeaxanthin includes multiple originator companies producing branded products primarily in the US market. Several branded formulations such as Macuvex, Macuzin, Ocuvel, and Tozal suggest established presence in this region. Patent expirations have likely allowed for existing or potential generic competition within the US market.